NCT01973049 / 2013-002458-66: UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis |
|
|
| Completed | 3 | 202 | US, Canada, Europe, RoW | Daclatasvir, BMS-790052, Asunaprevir, BMS-650032, BMS-791325, Ribavirin, Ribasphere®, Placebo matching Ribavirin | Bristol-Myers Squibb | Hepatitis C | 08/14 | 11/14 | | |